Immune Defense Protein for Common Cold

Overseen By Azure Grant

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Quantec Ltd

Must not be taking: Corticosteroids, Biologics, Chemotherapy, others

Disqualifiers: Immunocompromised, Asthma, COPD, others

Compensation: Varies

Number of Visits: Unknown

Duration: 17 weeks

300 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.

Are You a Good Fit for This Trial?

Inclusion Criteria

Able to read, understand, and provide informed consent

Able to use a personal smartphone device and download Chloe by People Science

Able to receive shipment of the product at an address within the United States

Exclusion Criteria

I do not have other health conditions that could affect study results.

Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes

Use of cannabis-containing products daily

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either the IDP® Supplement or a placebo to evaluate its impact on upper respiratory symptoms, rescue medication use, and quality of life

17 weeks

Self-reported measures and questionnaires completed at home via the Chloe App

Follow-up

Participants are monitored for safety and effectiveness after treatment, focusing on the tolerability of the IDP® Supplement

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Immune Defense Protein

How Is the Trial Designed?

Group I: Group 2: Study Product 200mg Dose Experimental Treatment 1 Intervention

200mg of Study Product

Group II: Group 1: Study Product 50mg Dose Experimental Treatment 1 Intervention

50mg of Study Product

Group III: Group 3: Matching Placebo Placebo Group 1 Intervention

Participants will receive Matching Placebo

Who Is Running the Clinical Trial?

Quantec Ltd

Lead Sponsor

People Science, Inc.

Industry Sponsor

Trials

7

Recruited

730+